---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-212128"
form_type: "8-K"
ticker: "INAB"
cik: "0001740279"
company_name: "IN8BIO, INC."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:54:02.634030+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# IN8bio Q1 2026 net loss $5.1M; GBM mPFS improved 97% vs SOC; cash $21.9M

## Summary
- Net loss of $5.1M ($0.26/sh) vs $5.6M ($2.16/sh) in Q1 2025; cash $21.9M up from $11.9M.
- GBM Phase 1/2: median PFS 13.0 months (repeat dose) vs 6.6 SOC (+97%); mOS still climbing at 17.2+ months.
- INB-619 TCE platform progressing toward IND; initial animal data expected in 2026.
- Anticipated FDA guidance on GBM regulatory pathway in 2H26; updated mOS data at ASCO 2026.
- R&D expenses $2.6M (down from $3.0M) on lower INB-400 clinical activity.

## SEC filing metadata
- accession: 0001193125-26-212128
- form_type: 8-K
- ticker: INAB
- cik: 0001740279
- company_name: IN8BIO, INC.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1740279/000119312526212128/0001193125-26-212128-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1740279/000119312526212128/inab-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-212128
- JSON: https://secwatch.observer/filing/0001193125-26-212128.json
- Plain text: https://secwatch.observer/filing/0001193125-26-212128.txt

## Source-grounded claims
- claim_id: 3e73406da0c08c9f38d70c6c18139c52413cee38
  claim: IN8BIO, INC. reported the first quarter ended March 31, 2026 results: net income a net loss of $5.1 million, or $0.26 per basic and diluted common share, EPS $0.26 per basic and diluted common share.
  evidence_excerpt: The Company reported a net loss of $5.1 million, or $0.26 per basic and diluted common share, for the three months ended March 31, 2026, compared with a net loss of $5.6 million, or $2.16 per basic and diluted common share, for the comparable prior year period.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1740279/000119312526212128/0001193125-26-212128-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.